For metastatisk pancreascancer var medianoverlevelsestiden for patienter behandlet med Tarceva 5, 9 måneder sammenlignet med 5, 1 måneder for patienter behandlet med placebo.
For metastatic pancreatic cancer, the mediansurvival in the patients treated with Tarceva was 5.9 months, compared to 5.1 months in those taking placebo.